ARQT - Company ID 0001787306
Arcutis Biotherapeutics, Inc. trades as ARQT and has a market capitalization of $3.57 B, making it the #1692 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $376.07M, up 91.3% from the prior year and net income of -$16.14M. This page tracks Arcutis Biotherapeutics, Inc. through 793 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -8449.8% to -4.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider trade | 4 | 2026-05-06 |
| Insider trade | 4 | 2026-05-06 |
| Insider trade | 4 | 2026-05-06 |
Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025
Q4 2025 net product revenue for ZORYVE ® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025
A live webcast of the call and related presentation materials will be available on the “ Events ” section of the Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.
The largest companies sharing Arcutis Biotherapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of $3.57 B as of 2026-07-09, ranking #1692 among US-listed companies.
Arcutis Biotherapeutics, Inc. reported revenue of $376.07M for fiscal year 2025, an increase of 91.3% year over year.
In its latest fiscal year Arcutis Biotherapeutics, Inc. reported a net loss of $16.14M.